Ates have been typically higher for imatinib-intolerant versus imatinib-resistant sufferers. CHR and
Chemexpress Ates had been frequently greater for imatinib-intolerant versus imatinib-resistant individuals. CHR and MCyR response prices had been comparable between older (aged 65 years) and younger (aged 65 years) patients, as…